默沙东拟分拆业务，成立独立癌症业务部门

Core Viewpoint - Merck announced a business split to create an independent division for its cancer business led by the blockbuster drug Keytruda, while separating its non-oncology treatment business [1] Group 1: Business Structure - The new cancer division will focus on Keytruda, which has been approved for multiple cancers and is currently the world's best-selling prescription drug [1] - Keytruda is projected to generate over $30 billion in revenue by 2025, accounting for nearly half of the company's total revenue [1] Group 2: Market Challenges - Merck previously warned that several traditional drugs are nearing the end of their patent protection and will face pressure from generic drugs, leading to lower-than-expected sales and profits [1]